Molecular grading of ductal carcinoma in situ of the breast

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8244-8252

  Balleine, Rosemary L ^a,b,c   Webster, Lucy R ^a,b,c   Davis, Sean ^d   Salisbury, Elizabeth L ^a   Palazzo, Juan P ^e   Schwartz, Gordon F ^e   Cornfield, Dennis B ^f   Walker, Robert L ^d   Byth, Karen ^b   Clarke, Christine L ^a,b,c   Meltzer, Paul S ^d  

^a Western Sydney Area Health Service   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NATIONAL CANCER INSTITUTE   (United States)

^e THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^f LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ARTICLE; BREAST DISEASE; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE COURSE; DNA FINGERPRINTING; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MICRODISSECTION; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; BREAST TUMOR; CARCINOMA IN SITU; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETICS; PAGET NIPPLE DISEASE; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; MICRODISSECTION;

EID: 58149340467     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0939     Document Type: Article

References (39)

1. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 2005;14:1008-11.
2. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-54.
3. ErnsterVL, BarclayJ, Kerlikowske K,Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000;160:953-8.
4. Duffy SW, Agbaje O,Tabar L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiag-nosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 2005;7:258-65.
5. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350:1430-41.
6. Elledge RM, McGuireWL, Osborne CK. Prognostic factors in breast cancer. Semin Oncol1992;19:244-53.
7. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999;31:209-23.
8. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999 -2009.
9. Shoker BS, Sloane JP. DCIS grading schemes and clinical implications. Histopathology 1999;35:393 -400.
10. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer1989;63:731 -41.
11. BobrowLG,HapperfieldLC,GregoryWM,MillisRR. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995;176:333-41.
12. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-61.
13. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2002;2:19 -27.
14. Leong AS, Sormunen RT,Vinyuvat S, Hamdani RW, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 2001;115:709 -18.
15. Webster LR, Bilous AM,Willis L, et al. Histopatho-logic indicators of breast cancer biology: insights from population mammographic screening. Br J Cancer 2005;92:1366 -71.
16. Elston CW,EllisIO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology1991;19:403 -10.
17. Consensus Conference Committee. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997;80:1798-802.
18. Sotiriou C,Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262 -72.
19. Lipson D, Aumann Y, Ben-Dor A, Linial N,Yakhini Z. Efficient calculation of interval scores for DNA copy number dataanalysis. JComput Biol 2006;13:215-28.
20. LiawA,Wiener M. Classification and regression by randomForest. R News 2002;2:18-22.
21. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317 -27.
22. Brieman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont (CA): Wadsworth;1984.
23. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
24. Silverstein MJ, Poller DN,Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet1995;345:1154-7.
25. Quinn CM, Ostrowski JL. Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast. J Clin Pathol 1997;50:596 -9.
26. Harrison M, Coyne JD, Gorey T, Dervan PA. Comparison of cytomorphological and architectural heterogeneity in mammographically-detected ductal carcinoma in situ. Histopathology 1996;28:445-50.
27. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006;8:R61.
28. Nishidate T, Katagiri T, Lin ML, et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. IntJ Oncol 2004;25:797 -819.
29. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006;66:5278-86.
30. Ma XJ, Salunga R,Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003;100:5974-9.
31. Ivshina AV, George J, Senko O, et al. Genetic reclas-sification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292 -301.
32. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004;101:9309-14.
33. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996;14:754-63.
34. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481 -4.
35. Silverstein MJ, Cohlan BF, Gierson ED, et al. Duct carcinoma in situ: 227 cases without microinvasion. EurJ Cancer1992;28:630-4.
36. Fisher ER, Dignam J,Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer1999;86:429 -38.
37. Fisher B, Dignam J,Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441 -52.
38. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III Trial 10853-A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381 -7.
39. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007;12:479-91.